While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several challenges associated with treating elderly patients in these disease settings. The presence of comorbidities, as well as the risk of treatment-related toxicities, makes the treatment of elderly patients an important area of research.

In this podcast, Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, and Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discuss challenges with classifying frailty in elderly patients with diffuse large B-cell lymphoma (DLBCL) and HL, as well as treatment options available to these patients.